PubHawk
Exp Mol Med December 2018 PMID 30546008

Immune checkpoint inhibitors: recent progress and potential biomarkers.

Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord

Download social card

Mentions

7
Peak: 1 in Jul 2019
across 3 sources since Jul 2019

Extended reach

144
potential audience

Total likes

1

Video views

18

Mentions per month

Jul 2019 – Oct 2023

Where it's discussed

  • News4 articles
  • X / Twitter2 posts
  • YouTube1 videos

AI synopsis

What people are saying

Participants generally agree on the importance of the advancements described, with comments highlighting the potential for improved patient outcomes through biomarker development. The tone emphasizes the significance by using words like 'promising,' 'needed,' and 'transformative,' underlining both interest and engagement with the topic’s future impact.

AgreementModerate agreement

Most discussions acknowledge the significance of recent advances in immune checkpoint inhibitors and see their potential as promising treatment options.

InterestHigh interest

Participants show high interest, frequently referencing the importance of biomarkers and the future of personalized cancer therapies.

EngagementModerate engagement

The posts include detailed analysis of the research, mentioning specific factors like PDL1 levels and neoantigens, indicating active engagement.

ImpactModerate impact

The discussions reflect a recognition that this research could greatly influence future treatments and clinical practices in oncology.

Abstract in brief

  • Recent advances in immune checkpoint inhibitors, such as PD1/PDL1 and CTLA4, have shown promising results in cancer treatment, but their effectiveness varies among patients, and some experience serious side effects.
  • The low response rates and adverse events highlight the need for reliable biomarkers that can predict which patients will benefit from these therapies, including factors like immune cell activity, PDL1 levels, neoantigens, and genetic signatures.
  • Developing robust predictive biomarkers will improve patient selection and help tailor immunotherapy treatments, making cancer treatment more effective and personalized.
Read the full abstract

Top posts

Most liked on X and Bluesky
Gabe King, CSNC
@gabebikes · X

Immune checkpoint inhibitors: recent progress and potential biomarkers - PubMed https://t.co/nbmgS5eHbX

Jun 5, 2023 · 126 followers View post →
lymphaticpapers
@lymphaticpaper · X

Immune checkpoint inhibitors: recent progress and potential biomarkers. https://t.co/HWd01xM0gQ

Jul 23, 2019 View post →

All mentions

Gabe King, CSNC
@gabebikes · X

Immune checkpoint inhibitors: recent progress and potential biomarkers - PubMed https://t.co/nbmgS5eHbX

Jun 5, 2023 · 126 followers View post →
lymphaticpapers
@lymphaticpaper · X

Immune checkpoint inhibitors: recent progress and potential biomarkers. https://t.co/HWd01xM0gQ

Jul 23, 2019 View post →